Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UltraInflamX Plus 360
- Development stage
- Unknown
- Lead developer
- Metagenics
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Administration
- Oral
01
Overview
UltraInflamX Plus 360 is a medical food developed by Metagenics specifically for the nutritional management of patients with compromised gut function, such as those with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. It is formulated as a powdered beverage containing a vegan pea/rice protein base supplemented with a comprehensive blend of micronutrients and phytonutrients. Key bioactive components include CurQfen (a high-bioavailability curcumin blend) and XNT ProMatrix (a proprietary xanthohumol delivery system), alongside ginger, quercetin, and L-glutamine. The product aims to address nutrient deficiencies, support gut barrier integrity, and provide general anti-inflammatory effects through the modulation of inflammatory pathways and leukocyte subtypes.
- Brand names
- UltraInflamX Plus 360
- Other names
- UltraInflamX Plus 360°
02
Targets
NF-κBTNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on UltraInflamX Plus 360.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UltraInflamX Plus 360.